JP2002503963A - ヒト腫瘍壊死因子受容体ｔｒ９ - Google Patents

ヒト腫瘍壊死因子受容体ｔｒ９

Info

Publication number
JP2002503963A
JP2002503963A JP50309999A JP50309999A JP2002503963A JP 2002503963 A JP2002503963 A JP 2002503963A JP 50309999 A JP50309999 A JP 50309999A JP 50309999 A JP50309999 A JP 50309999A JP 2002503963 A JP2002503963 A JP 2002503963A
Authority
JP
Japan
Prior art keywords
amino acid
polypeptide
sequence
seq
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP50309999A
Other languages
English (en)
Japanese (ja)
Inventor
ニ，ジャン
ユ，グオ−リアン
ファン，ピン
ジェンツ，ライナー・エル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of JP2002503963A publication Critical patent/JP2002503963A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
JP50309999A 1997-06-11 1998-06-10 ヒト腫瘍壊死因子受容体ｔｒ９ Withdrawn JP2002503963A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5299197P 1997-06-11 1997-06-11
US60/052,991 1997-06-11
PCT/US1998/011932 WO1998056892A1 (fr) 1997-06-11 1998-06-10 Recepteur humain tr9 du facteur de necrose tumorale

Publications (1)

Publication Number Publication Date
JP2002503963A true JP2002503963A (ja) 2002-02-05

Family

ID=21981206

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50309999A Withdrawn JP2002503963A (ja) 1997-06-11 1998-06-10 ヒト腫瘍壊死因子受容体ｔｒ９

Country Status (5)

Country Link
EP (1) EP0988371A4 (fr)
JP (1) JP2002503963A (fr)
AU (1) AU7830398A (fr)
CA (1) CA2295991A1 (fr)
WO (1) WO1998056892A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
WO1997033904A1 (fr) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Recepteurs contenant un domaine de mort cellulaire
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
ATE365796T1 (de) 1997-01-14 2007-07-15 Human Genome Sciences Inc Tumornekrosefaktor-rezeptoren 6 alpha& 6 beta
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
US6949358B1 (en) 1997-06-11 2005-09-27 Human Genome Sciences, Inc. Human tumor necrosis factor receptor TR9
US6358508B1 (en) 1997-06-11 2002-03-19 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR9
US6194151B1 (en) 1997-09-26 2001-02-27 Millenium Pharmaceuticals, Inc. Molecules of the TNF receptor superfamily and uses therefor
GB9812607D0 (en) * 1998-06-12 1998-08-12 Zeneca Ltd Protein
US6916907B1 (en) 1998-10-23 2005-07-12 Curagen Corporation Nucleic acids encoding osteoprotegern-like proteins and methods of using same
WO2000034294A2 (fr) * 1998-12-11 2000-06-15 Bristol-Myers Squibb Company Homologue recepteur du facteur de necrose tumorale (trh1)
EP2357192A1 (fr) 1999-02-26 2011-08-17 Human Genome Sciences, Inc. Endokine alpha humain et methodes d'utilisation
WO2000056862A1 (fr) * 1999-03-24 2000-09-28 Human Genome Sciences, Inc. Recepteur tr9 humain de facteurs de necrose des tumeurs
HUP0300369A2 (hu) 2000-04-11 2003-06-28 Genentech, Inc. Többértékű antitestek és alkalmazásuk
JP2003530839A (ja) 2000-04-12 2003-10-21 プリンシピア ファーマスーティカル コーポレイション アルブミン融合タンパク質
AU2001257008A1 (en) * 2000-05-10 2001-11-20 Eli Lilly And Company Treating t-cell mediated diseases by modulating dr6 activity
EP2431054A3 (fr) 2000-06-15 2013-03-06 Human Genome Sciences, Inc. Facteur delta de nécrose de tumeur humaine et epsilon
ATE494304T1 (de) 2000-06-16 2011-01-15 Human Genome Sciences Inc Immunspezifisch bindende antikörper gegen blys
AU2002309647C1 (en) 2001-05-25 2008-09-11 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
EP2277910A1 (fr) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Protéines de fusion d'albumine
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20070086979A1 (en) 2005-10-13 2007-04-19 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
NZ592070A (en) 2008-09-26 2012-07-27 Tocagen Inc Gene therapy vectors and humanized yeast cytosine deaminase triple mutant
MX2011005481A (es) 2008-11-25 2011-08-17 Biogen Idec Inc Uso de antagonistas de receptor de muerte 6 (drg6) y de p75 para promover la supervivencia de células del sistema nervioso.
AU2011329647B2 (en) 2010-11-19 2015-10-22 Eisai R&D Management Co., Ltd. Neutralizing anti-CCL20 antibodies
ES2786051T3 (es) 2012-10-25 2020-10-08 Tocagen Inc Vector retroviral con casete de mini-promotor
JP2023507922A (ja) 2019-12-03 2023-02-28 上海交通大学医学院 ＦｃγＲＩＩＢ親和性が増強された抗体Ｆｃ領域

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
EP0394827A1 (fr) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Polypeptides chimériques de CD4-immunoglobuline
US5462856A (en) 1990-07-19 1995-10-31 Bunsen Rush Laboratories, Inc. Methods for identifying chemicals that act as agonists or antagonists for receptors and other proteins involved in signal transduction via pathways that utilize G-proteins
WO1994009137A1 (fr) 1992-10-15 1994-04-28 Genentech, Inc. Anticorps contre le recepteur du facteur de necrose de tumeurs de type 2
US6358508B1 (en) * 1997-06-11 2002-03-19 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR9
WO1999011790A1 (fr) * 1997-09-04 1999-03-11 Zymogenetics, Inc. Recepteur ztnfr-6 du facteur de necrose des tumeurs
WO2000056862A1 (fr) * 1999-03-24 2000-09-28 Human Genome Sciences, Inc. Recepteur tr9 humain de facteurs de necrose des tumeurs

Also Published As

Publication number Publication date
AU7830398A (en) 1998-12-30
EP0988371A4 (fr) 2002-11-04
WO1998056892A1 (fr) 1998-12-17
CA2295991A1 (fr) 1998-12-17
EP0988371A1 (fr) 2000-03-29

Similar Documents

Publication Publication Date Title
KR100527638B1 (ko) 사망 도메인을 보유하는 수용체 5
JP2002503963A (ja) ヒト腫瘍壊死因子受容体ｔｒ９
JP4450870B2 (ja) 死ドメイン含有レセプター４（ｄｒ４：死レセプター４）、ｔｎｆ−レセプタースーパーファミリーのメンバーおよびｔｒａｉｌへの結合
US6759513B2 (en) Death domain containing receptors
JP2001507937A (ja) 腫瘍壊死因子レセプター６αおよび腫瘍壊死因子レセプター６β
US20050239123A1 (en) Human tumor necrosis receptor TR9
WO1998018824A9 (fr) Recepteur tr2 du facteur de necrose tumorale chez l'homme
EP1788086A1 (fr) Récepteur 5 contenant un domaine de mort
AU2006246525A1 (en) Death Domain Containing Receptor 5
MXPA99008486A (en) Death domain containing receptor 5
EP0898576A1 (fr) Recepteurs contenant un domaine de mort cellulaire

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050525

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20060307